Aizon, an enterprise AI software provider, announced today the creation of a Strategic Advisory Board (SAB) made up of four world-renowned executives from the pharmaceutical and healthcare industries. New members include Michele d’Alessandro, Jerh Collins, Dr. Antonio Moreira and Matthias Pohl.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005372/en/
Aizon Strategic Advisory Board, comprised by Michele d'Alessandro, Merck; Jehr Collins, Novartis; Dr. Tony Moreira, University of Maryland and ISPE and Matthias Pohl, InterPharmaLink. (Photo: Business Wire)
The Board is engaged in support of Aizon’s mission to help pharmaceutical and biotech companies transform their manufacturing operations with the use of advanced analytics, artificial intelligence (AI), machine learning (ML) and other smart factory technologies. Its members will provide strategic counsel to Aizon’s executive team and open up access to their networks to strengthen the company’s relationships with key customers and partners.
“We have a real opportunity to help pharmaceutical and biotech companies start their digital transformation journeys toward Pharma 4.0 in an easy and measured approach,” said John Vitalie, CEO, Aizon. “We look forward with excitement to their future contributions to the achievement of Aizon’s strategic corporate and product objectives, and to gain the knowledge and insights derived from their decades of using innovative technology and real-time data analytics to transform the pharma and healthcare industries.”
The four members of the board include:
- Michele d'Alessandro, Vice President and CIO of Manufacturing IT at Merck, is responsible for information technology and digital solutions for the Merck Manufacturing Division. This includes Small Molecule, Large Molecule and Sterile/Biologics lines of business, as well as the enabling functions of supply chain, external manufacturing, global science, technology, commercialization and global quality.
- Chief Culture Officer at Novartis Jerh Collins, where he is responsible for scaling the company’s people and culture initiatives while integrating culture in the flow of work. He was previously Head of Global Chemical Operations & Anti-infectives at Novartis where he was responsible for the Global Small Molecules and Anti-infectives site network.
- Antonio (Tony) Moreira, PhD is Vice Provost for Academic Affairs at the University of Maryland and Chair of the Board of the ISPE Foundation. Tony has 30 years experience in the biopharma sector and spent nearly 10 years in management positions with International Flavors and Fragrances and Schering-Plough Corp. (now Merck).
- Partner at InterPharmaLink Matthias Pohl brings strong experience in phases of start-up, stabilization, restructuring and expansions. He was previously Global Head of Health, Safety, Environment and Business Continuity Management at Novartis and Head of Global Quality at Sandoz where he helped restore relations with the FDA in 2013 after the company received a number of warning letters.
For more information on the Aizon Strategic Advisory Board, visit: https://www.aizon.ai/about/.
About Aizon
Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005372/en/
Contacts:
